期刊文献+

利拉鲁肽治疗2型糖尿病的系统评价 被引量:10

Systematic Review of GLP-1 Analogues—Liraglutide for Type 2 Diabetes Mellitus
下载PDF
导出
摘要 目的评价类胰高血糖素样肽-1类似物——利拉鲁肽治疗2型糖尿病的疗效与安全性。方法应用Cochrane系统评价方法,对Cochrane图书馆的Cochrane对照试验注册数据库、PubMed、EMBASE、TheNational Reseach Register、CurrentControlledTrials、中国生物医学文献数据库、中国期刊全文数据库、VIP,建库至2011年8月6日间的所有文献进行检索,查找符合纳入标准的随机对照试验进行质量评价,运用RevMan5.0统计软件对提取的相关数据进行Meta分析。结果最终纳入8个随机对照试验,共计3351例患者,并对其疗效和安全性进行了Meta分析,表明利拉鲁肽与对照组相比,能更有效降低糖化血红蛋白[标准化均数差=-5.34,95%可信区间(-6.92,-3.75),P<0.00001]和空腹血糖[标准化均数差=-0.80,95%可信区间(-0.94,-0.66),P<0.00001],能减轻体重[标准化均数差=-0.37,95%可信区间(-0.51,-0.22),P<0.00001],低血糖风险相似[相对危险度=1.2,95%可信区间(0.55,2.62),P=0.64];利拉鲁肽胃肠道反应更常见,但短暂而轻微。结论利拉鲁肽作为一种新的肠促胰岛激素类似物,能显著控制血糖、减轻体重,与对照组低血糖风险相似。但其胃肠道反应较常见,程度较轻而短暂。它为2型糖尿病患者提供了一种新的降糖药选择。 Objective To assess the efficacy and safety of GLP-1 analogues- Liraglutide for T2DM. Methods Based on the principles and methods of Cochrane systematic reviews, electronic database searching was performed on search The Coehrane Library, PubMed, EMBASE, The National Research Register, Current Controlled Trials, CBM, CNKI, VIP, and the data from the beginning of the database to June 8, 2011 were included. Randomized controlled trials(RCT) concerning Liraglutide for T2DM were selected and assessed for the methodological quality, and the extracted data were performed meta-anlysis by statistical software RevMan 5.0. Result Eight RCTs involving 3 351 patients met the inclusion criteria. Compared with control, Liraglutide showed significant positive effects on lowering hemoglobin Alc,FPG. The effect sizes were [SMD=-5.34,95%CI(-6.92,-3.75), P〈0.000 01~ and [SMD=-0.80, 95%CI(-0.94, -0.66), P〈0.000 011 respectively. Liraglutide resulted in weight loss[SMD=-0.37, 95%CI (-0.51,-0.22) ,P〈0.000 01 ]. For side effects Liraglutide had a similar risk of hypoglycemia with control [RR=I.2, 95%CI (0.55,2.62), P=0.64]. Adverse effects(AEs) were reported in included studies, the most of which were gastrointestinal reaction. And these events were mostly slight and transient. It suggested that Liraglutide was safe. Conclusions As a new incretin analogues,Liraglutide is more effective in lowering blood glucose than control. Furthermore, it resulted in weight loss and had similar risk of hypoglycemia. However its gastrointestinal reactions are more common than control which are mostly slight and transient. It offers an alternative option to currently available hypoglycemic agents for patients with T2DM.
出处 《循证医学》 CSCD 2012年第2期117-124,共8页 The Journal of Evidence-Based Medicine
关键词 糖尿病 类胰高血糖素样肽-1 肠促胰岛素 利拉鲁肽 系统评价 diabetes mellitus Glucagon like peptide-1 (GLP-1) ineretin Liraglutide systematic review
  • 相关文献

参考文献15

  • 1Drueker DJ, Nauek MA. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4inhibitors in type 2 diabetes [J]. Lancet, 2006,368 (9548) : 1696-1705. 被引量:1
  • 2Deacon CF, Knudsen LB, Madsen K, et al. Dipeptidyl peptidase 1V resistant analogues of glucagon-like peptide- 1 which have extended metabolic stability and improved biological activity [J]. Diabetologia, 1998,41 ( 3 ) : 271-278. 被引量:1
  • 3Chan JCN. Emerging treatment for the unmet needs in type 2 diabetes [J]. Diabetes Res Clin Practice, 2008,79 (suppl 1 ) : S8-S9. 被引量:1
  • 4吴泰相,刘关键.隐蔽分组(分配隐藏)和盲法的概念、实施与报告[J].中国循证医学杂志,2007,7(3):222-225. 被引量:174
  • 5Seino Y, Rasmussen MF, Zdravkovic M, et al. Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes [J]. Diabetes Res Clin Pract, 2008,81(2):161-168. 被引量:1
  • 6Feinglos MN, Saad MF, Pi-Sunyert FX, et a]. Effects of liraglutide ( NN2211 ), a long-aeting GLP- 1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes [J]. Diabet Med, 2005,22(8) : 1016-1023. 被引量:1
  • 7Madsbad S, Schmitz O, Ranstam J, et al. Improved gXycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-actingglucagon-like peptide lanalog liraglutide (NN2211): A 12- week, double-blind, randomized, controlled trial[J]. Diabetes Care, 2004,27(6) : 1335-1342. 被引量:1
  • 8Vilsboll T, Zdravkovic M, Le-Thi T, et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight witho.ut risk of hypoglycemia in patients with type 2 diabetes[J]. Diabetes Care, 2007,30(6) : 1608-1610. 被引量:1
  • 9Nauek M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: The LEAD (liraglutide effect and action in diabetes)-2 study I J]. Diabetes Care, 2009,32( 1 ) : 84-90. 被引量:1
  • 10Marre M, Shaw J, Brandle M,et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glyeaemic and weight control compared with adding msiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU)[J]. Diabet Med, 2009,26 (3) : 268-278. 被引量:1

二级参考文献6

  • 1Jadad AR. Randomised controlled trials, A user's guide.[2007-01-26]http://www.cgmh.org.tw/intr/intr5/c6700/OBGYN/F/Randomized%20tial/chapter I .html. 被引量:1
  • 2Chalmers TC, Celano P, Sacks HS, et al. Bias in treatment assignment in controlled clinical trials. N Engl J Med, 1983, 309:1359-1361. 被引量:1
  • 3Schulz KF, Chalmers I, Hayes RJ, et al. Empirical evidence of bias:dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA, 1995, 273: 408-412. 被引量:1
  • 4Schulz KF. Subverting randomization in controlled trials. JAMA,1995, 274: 1456-1458. 被引量:1
  • 5Pildal J, Chan AW, Hrebjartsson A, et al. Comparison of descriptions of allocation concealment in trial protocols and the published reports: cohort study. BM./, 2005, 330: 1049. 被引量:1
  • 6Moher D, Fortin P, Jadad AR, et al. Completeness of reporting of trials published in languages other than English: implications for conduct and reporting of systematic reviews. Lancet, 1996, 347:363-366. 被引量:1

共引文献173

同被引文献117

  • 1UngerRH. AIpha-and beta-cell interrelationships in health and disease[J].{H}Metabolism-Clinical and experimental,1974,(06):581-593. 被引量:1
  • 2Rossi ME,Nicolucd A. Liraglutide in type 2 diabetes:from pharmacological development to clinical practece[J].Acta Biomed,2009,(02):90-101. 被引量:1
  • 3Knudsen LR. Liraglutide:the therapeutic promise from animal models[J].{H}INTERNATIONAL Journal OF CLINICAL PRACTICE,2010,(167):4-11. 被引量:1
  • 4Schmidt WE. Early clinical studies with liraglufide[J].{H}INTERNATIONAL Journal OF CLINICAL PRACTICE,2010,(167):12-20. 被引量:1
  • 5卫生部疾病控制司.中国成人超重和肥胖症预防控制指南[M]{H}北京:人民卫生出版社,200633-34. 被引量:1
  • 6Russell Jones D,Simpson R,Hylleberg B. Effects of QD insulin detemir or neutral protamine hagedom on blood glucose control in patients with type 1 diabetes mellitus using a basal bolus regimen[J].Clin Thera,2004,(05):724-736. 被引量:1
  • 7Vilsboll T. The effects of glueagon-like peptide-1 on the beta cell[J].{H}Diabetes Obesity & Metabolism,2009,(z3):11-18. 被引量:1
  • 8Montanya E,Sesti Q. Areview of efficacy and safety data re garding the useof liraglutide,a once daily humanglucagon-like peptide 1 analogue.in the treatment of type 2 diabetes mellitus[J].{H}Clinical Therapeutice,2009,(11):2472-2488. 被引量:1
  • 9Gonzalez Perez A,Schlienger RG,Rodriguez LA. Acute pan creatitis in association with type 2 diabetes and antidiabetic drugs:a population-based cohort study[J].{H}DIABETES CARE,2010,(12):2580-2585. 被引量:1
  • 10Koehler JA,Baggio LL,Lamont BJ. Glucagon like peptide-1 receptor activation modulates pancreatitis aasociated gene expres sion but does notmodify the susceptibility to experimental pancrea titis in mice[J].{H}DIABETES,2009,(09):2148-2161. 被引量:1

引证文献10

二级引证文献88

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部